

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

NCT07304089

Status	RECRUITING
Phase	Phase 2
Sponsor	Vima Therapeutics
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (4)

- Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
- The participant has a clinical diagnosis of isolated dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee.
- The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria.
- The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.

Locations (37 total)

Vima Site #033, Birmingham, Alabama, United States
Vima Site #039, Scottsdale, Arizona, United States
Vima Site #004, Scottsdale, Arizona, United States
... and 34 more locations